Nonetheless, the use of combined p16 and MTAP IHC correctly predicted this molecular abnormality and, therefore, this could be a reliable method to assess for CDKN2A HD in PXA when molecular testing is not available. This evidence concerns the gene CDKN2A and pleomorphic xanthoastrocytoma.